RBBP9 Antibody

Code CSB-PA784892
Size US$166
Order now
Image
  • Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Mouse kidney tissue, A375 cells, Primary antibody: CSB-PA784892(RBBP9 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
RBBP9
Alternative Names
B5T overexpressed gene protein antibody; B5T-overexpressed gene protein antibody; BOG antibody; Bog protein antibody; MGC9236 antibody; OTTHUMP00000030360 antibody; Protein BOG antibody; Putative hydrolase RBBP9 antibody; RBBP 10 antibody; RBBP 9 antibody; RBBP-10 antibody; RBBP-9 antibody; RBBP10 antibody; RBBP9 antibody; RBBP9_HUMAN antibody; Retinoblastoma binding protein 10 antibody; Retinoblastoma binding protein 9 antibody; Retinoblastoma-binding protein 10 antibody; Retinoblastoma-binding protein 9 antibody; Retinoma binding protein 9 antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse,Rat
Immunogen
Fusion protein of Human RBBP9
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Isotype
IgG
Purification Method
Antigen affinity purification
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
Form
Liquid
Tested Applications
ELISA,WB
Recommended Dilution
Application Recommended Dilution
ELISA 1:1000-1:2000
WB 1:200-1:1000
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Serine hydrolase whose substrates have not been identified yet. May negatively regulate basal or autocrine TGF-beta signaling by suppressing SMAD2-SMAD3 phosphorylation. May play a role in the transformation process due to its capacity to confer resistance to the growth-inhibitory effects of TGF-beta through interaction with RB1 and the subsequent displacement of E2F1.
Gene References into Functions
  1. blood samples of lateral sclerosis patients were found to have significantly different levels of expression of CyFIP2 and RbBP9 compared to the levels of expression in control subjects. PMID: 22430187
  2. Structure- function studies of RBBP9 suggest possible routes for novel cancer drug discovery programs. PMID: 21933118
  3. Data identified RBBP4 and RBBP9 as required for maintenance of multiple PS cell types, and both RBBPs were bound to RB in PS cells. PMID: 21689726
  4. identify RBBP9 as a tumor-associated serine hydrolase that displays elevated activity in pancreatic carcinomas. RBBP9 promotes pancreatic carcinogenesis. PMID: 20080647
  5. RBBP10 was expressed widely in various human tissues, and the expression level is somewhat higher in tumor tissues than in normal tissues. PMID: 12296629
  6. The crystal structure of human RBBP9 has been determined at 1.72 A resolution by the seleno-methionyl single-wavelength anomalous diffraction method. PMID: 19004028

Show More

Hide All

Protein Families
RBBP9 family
Tissue Specificity
Expressed at higher levels in tumor tissues such as carcinoma.
Database Links

HGNC: 9892

OMIM: 602908

KEGG: hsa:10741

STRING: 9606.ENSP00000336866

UniGene: Hs.69330

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*